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Abstract: 
1-Aryl- and 2-aryl-1,2,3-triazoles were synthesized by N-arylation of the corresponding 
azoles using aryl iodides. The deprotometalations of 1-phenyl-1,2,3-triazole and -1,2,4-
triazole were performed using a 2,2,6,6-tetramethylpiperidino-based mixed lithium-zinc 
combination and occurred at the most acidic site, affording by iodolysis the 5-substituted 
derivatives. Dideprotonation was noted from 1-(2-thienyl)-1,2,4-triazole by increasing the 
amount of base. From 2-phenyl-1,2,3-triazoles, and in particular from 2-(4-
trifluoromethoxy)phenyl-1,2,3-triazole, reactions at the 4 position of the triazolyl, but also 
ortho to the triazolyl on the phenyl group, were observed. The results were analyzed with the 
help of the CH acidities of the substrates, determined in THF solution using the DFT B3LYP 
method. 4-Iodo-2-phenyl-1,2,3-triazole and 4-iodo-2-(2-iodophenyl)-1,2,3-triazole were next 
involved in Suzuki coupling reactions to furnish the corresponding 4-arylated and 4,2’-
diarylated derivatives. When evaluated for biological activities, the latter (which are 
resveratrol analogues) showed moderate antibacterial activity and promising antiproliferative 
effect against MDA-MB-231 cell line. 
Keywords: triazole, deprotonative metalation, CH-acidity, resveratrol analogue, 
antiproliferative activity 
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1. Introduction 
Di- and triazoles are key elements present in compounds of biological interest1 or in 
materials for a wide range of applications.1a,b,2 
Aromatic deprotonative lithiation3 is an efficient tool to functionalize regioselectively 
heterocycles.4 Concerning 1-substituted 1,2,3- and 1,2,4-1H-triazoles, such a possibility has 
been developed, affording after subsequent trapping 5-substituted derivatives.4q 
Combinations of lithium reagents and softer metal compounds have recently emerged as 
efficient tools to deprotometalate sensitive aromatic compounds.5 In the framework of these 
studies, we developed efficient pairs of metal amides which complement each other in 
deprotometalation reactions. In particular, the TMP-based (TMP = 2,2,6,6-
tetramethylpiperidino) lithium-zinc mixture,6 prepared by mixing LiTMP with ZnCl2·TMEDA 
(1/3 equiv, TMEDA = N,N,N',N'-tetramethylethylenediamine) and supposed to be a 1:1 
Zn(TMP)2-LiTMP·2LiCl(±TMEDA) mixture,
7 was identified as a suitable reagent to 
functionalize sensitive aromatic compounds including heterocycles. 
We herein describe our attempts to use the lithium-zinc combination above mentioned for 
the deprotometalation (followed by iodolysis) of the azole substrates 1 and 2 shown in 
Scheme 1. Earlier we have shown that the regioselectivity of the same reaction for the related 
substrates 36f and 46h is partly determined by the acidity of the different hydrogens in their 
molecules. As a consequence, we similarly tried to rationalize the reaction results using the 
CH acidities in THF of the heteroaromatic substrates calculated by using the homodesmic 
reaction approach within the density functional theory (DFT) framework. Finally, iodides 
generated by deprotometalation-iodolysis were involved in palladium-catalyzed Suzuki cross-
coupling reactions, and the resulting arylated triazoles (which are resveratrol analogues) were 
evaluated for their biological activity. 
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Scheme 1. Substrates for which the deprotometalation has been studied. 
2. Results and Discussion 
2.1. Synthetic aspects 
1-Phenyl-1H-1,2,3-triazole (1a) was prepared by adapting a procedure described.8 To reach 
the target substrates 2, the unsubstituted azoles were treated with aryl and heteroaryl halides 
under copper catalysis using the conditions reported by Buchwald and co-workers (Scheme 
2).9 Moderate to excellent yields were noted, with aryl iodides favoring the reaction as 
observed previously.6l 
N
H
N
N
+   Ph-I N
N
N
Ph
Cu2O (10 mol.%)
TMAF (3 equiv)
1,10-phenanthroline (20 mol.%)
120 °C
1a: 47%
N
H
N
N
+   Ar-X N
N
N
Ar
CuI (5 mol.%)
K3PO4 (2 equiv)
MeNH(CH2)2NHMe (10 mol.%)
DMF, 110 °C
2a (Ar = Ph, X = I): 96%
2b (Ar = 2-thienyl): 70% (X = I), 61% (X = Br) 
Scheme 2. Synthesis of 1a, 2a and 2b. 
Upon treatment in THF for 2 h at room temperature with the lithium-zinc base, in situ 
prepared from ZnCl2·TMEDA (x equiv) and LiTMP (3x equiv), 1-phenyl-1H-pyrazole (3a) is 
mainly deprotonated at its 5 position (x = 0.5), a result evidenced by subsequent interception 
with iodine.6c,6f In addition, 2-phenyl-2H-1,2,3-triazole (4a) mainly led to the 4-iodo derivative 
under the same reaction conditions.6h It was thus of interest to attempt the reaction from 1-
phenyl-1H-1,2,3-triazole (1a) and 1-phenyl-1H-1,2,4-triazole (2a). In both cases, the reaction 
took place at the 5 position of the triazolyl group, and the iodides 5a (x = 0.75) and 6a (x = 
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0.5) were isolated in 89 and 51% yield, respectively (Scheme 3). The iodide 5a was also 
isolated (80% yield) from 1a after carrying out the reaction using LiTMP (1.5 equiv) in THF, 
but using a lower (-20 °C) reaction temperature. 
1) ZnCl2·TMEDA (x equiv)
+ LiTMP (3x equiv)
THF, rt, 2 h
2) I2
HetAr-H HetAr-I
N
N
N
Ph
N
N
Ph
N
N
N
Ph
1a 2a
56% yield
(x = 0.5)
N
NN
Ph
38% yield
(x = 0.5)
89% yield
(x = 0.75)
51% yield
(x = 0.5)
3a 4a  
Scheme 3. Deprotometalation followed by iodolysis on N-phenylpyrazole and different N-
phenyltriazoles. 
By replacing the phenyl group connected to the 1,2,4-triazole by a 2-thienyl group 
(substrate 2b), a reaction at the 5 position of the aza-heterocycle was still observed, as 
demonstrated by the isolation of the corresponding iodide 6b in 95% yield. By increasing the 
amount of base (0.75 equiv of ZnCl2·TMEDA and 2.25 equiv of LiTMP instead of 0.5 equiv 
of ZnCl2·TMEDA and 1.5 equiv of LiTMP), the iodide 6b became the minor product formed 
(8% yield) due to competitive dideprotometalation, as previously noted in the other azole 
series.6f,6h Indeed, the diiodides 7b and 7b' were obtained in 59 and 28% yield, respectively 
(Scheme 4). The iodides 5a and 6a, as well as the major isomer 7b, were identified 
unequivocally by X-ray structure analysis (Figure 1). 
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1) ZnCl2·TMEDA (0.5 equiv)
+ LiTMP (1.5 equiv)
THF, rt, 2 h
2) I2
N
N
N
2b
6b
8% yield
S
N
N
N
S
I
1) ZnCl2·TMEDA
(0.75 equiv)
+ LiTMP (2.25 equiv)
THF, rt, 2 h
2) I2
2b
N
N
N
S
I
I
6b: 95% yield
7b: 59% yield
N
N
N
S
I
7b': 28% yield
I
 
Scheme 4. Deprotometalation of 2b followed by iodolysis. 
Figure 1. ORTEP diagram (50% probability) of 5a, 6a and 7b. 
  
The triazole moiety is a well-known bioisostere of amide and ester groups and a linker 
replacement of double bonds.10 In addition, resveratrol is a compound with a versatile 
biological activity.11 In order to progress towards triazole-modified resveratrol analogues 
(Scheme 5, A), 2-(4-trifluoromethoxyphenyl)-1,2,3-triazole (8) was identified as a good 
precursor due to the impact of the trifluoromethoxy group on the biological activity of the 
derivatives.12 It was synthesized by regioselective palladium-catalysed N-arylation of 1,2,3-
triazole at its N2 position using 1-bromo-4-(trifluoromethoxy)benzene under conditions 
described by Buchwald and co-workers.13 Unfortunately, treatment of 8 by the base (0.5 equiv 
of ZnCl2·TMEDA and 1.5 equiv of LiTMP) as before led, after addition of iodine, to a 
mixture from which only pure 2-(2-iodo-4-trifluoromethoxyphenyl)-1,2,3-triazole (9a) could 
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be isolated. Analyzing the crude showed, besides the monoiodide 9a (estimated 25% yield), 
the formation of the diiodide 10 and the monoiodide 9b (in estimated 21 and 6% yield, 
respectively) and the recovery of substrate (about 33% yield) (Scheme 6).  
N
NN
Ar1
Ar2
A
OH
OHHO
resveratrol
N
NN
Ar1
I
 
Scheme 5. Resveratrol and planned analogues (A). 
1) ZnCl2·TMEDA
(0.5 equiv)
+ LiTMP (1.5 equiv)
THF, rt, 2 h
2) I2
8
9a: 25% yield 10: 21% yield
N
H
NN +
N
NN
Pd2(dba)3 (0.75 mol.%)
ligand (1.8 mol.%)
K3PO4 (2 equiv)
toluene, 120 °C
8: 96%
Br
OCF3 OCF3
N
NN
OCF3
N
NN
OCF3
I I
I
9b: 6% yield
N
NN
OCF3
I
 
Scheme 6. Deprotometalation of 8 followed by iodolysis. 
This disappointing result led us to rather consider the synthesis of targets without 
trifluoromethoxy group. We thus chose 2-phenyl-1,2,3-triazole (4a), and synthesized the 
monoiodide 4b and diiodide 4b’ as described previously.6h The monoiodide 4b was first 
reacted with arylboronic acids (stoichiometric amount) in a Suzuki-type cross-coupling 
procedure14 using catalytic Pd(dba)2 (dba = dibenzylidene acetone) and triphenylphosphine, 
dioxane as solvent and CsF instead of a base to afford the compounds 4c,d in 54-70% yields. 
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For easier purification, we turned to a dba-free reported procedure15 using catalytic PdCl2 and 
triphenylphosphine, a biphasic medium and Na2CO3 as a base, and isolated the arylated 
compounds 4e,f in 87-98% yields (Scheme 7). The structures of the compounds 4d and 4e 
were confirmed by X-ray diffraction (Figure 2). 
N
NN
Ph
ArB(OH)2 (1 equiv)
Pd(dba)2 (5 mol.%)
PPh3 (10 mol.%)
CsF (2 equiv)
dioxane, 105 °C
4c (Ar = Ph): 70%
4d (Ar = C6H3-2,5-(OMe)2): 54%
I
N
NN
Ph
Ar
4b
ArB(OH)2 (1 equiv)
PdCl2 (2 mol.%)
PPh3 (6 mol.%)
Na2CO3 (2 equiv)
H2O, EtOH, DME, reflux
4e (Ar = C6H4-4-OH): 98%
4f (Ar = C6H4-4-NH2): 87%
N
NN
Ph
Ar
4b
 
Scheme 7. Suzuki-type cross-coupling from 4b. 
Figure 2. ORTEP diagram (50% probability) of 4d and 4e. 
  
When involved in the reaction, the diiodide 4b’ led to a complex mixture due to 
unselective mono-coupling. We decided to employ the arylboronic acid in excess (4 equiv) in 
order to synthesize the bis-coupling products. Thus, the bis-arylated derivatives were obtained 
in yields ranging from 73 to 92% (Scheme 8). 
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N
NN
I
ArB(OH)2 (4 equiv)
PdCl2 (2 mol.%)
PPh3 (6 mol.%)
Na2CO3 (2 equiv)
H2O, EtOH, DME, reflux
4c' (Ar = Ph): 90%
4d' (Ar = C6H4-4-OMe): 75%
4e' (Ar = C6H4-4-OH): 92%
4f' (Ar = C6H4-4-NH2): 73%
4g' (Ar = C6H4-3-Cl): 83%
4b'
I
N
NN
Ar
Ar
 
Scheme 8. Suzuki-type cross-coupling from 4b’. 
2.2. Computational aspects 
The studies on CH acidity of triazoles and their derivatives are not numerous. A brief 
review of papers devoted to experimental and theoretical investigation of CH acidity of azoles 
is presented in our previous publication.16 Fraser reported the pKa value (26.2) of 1-propyl-1H-
1,2,4-triazole in THF solution.17 Gas-phase deprotonation energies for several triazoles were 
estimated by means of semi-empirical calculations.18 We also recently contributed to this field 
by DFT computed values for substituted triazoles,19 N-aryl triazoles,6h N-aryl pyrazoles6f and 
N-aryl benzotriazoles.6l 
In the present paper, the DFT calculated CH acidities of several N-aryl triazoles, both in 
gas phase (see Supplementary data) and in THF solution (Scheme 9), are presented. These 
DacidG and pKa values were obtained by using the theoretical protocol described thoroughly 
previously.16 
1a
N
N
N
S
36.6
27.7
38.4
41.2
41.8
40.9
36.8
N
N
N
36.2
28.4
38.9
41.5
42.1
41.1
37.0
35.0
27.1
32.6
36.3 30.2
2a 2b
N N
N
OCF3
8
N
N
N
33.733.7
35.8
33.3
35.8
33.4
 
Scheme 9. Calculated values of pK
a
(THF) of the investigated compounds. 
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All the calculations were performed by using the DFT B3LYP method. The geometries 
were optimized using the 6-31G(d) basis set. No symmetry constraints were applied. In order 
to perform stationary points characterization and to calculate zero-point vibrational energies 
(ZPVE) and thermal corrections, vibrational frequencies were calculated at the same level of 
theory. The single point energy calculations were performed using the 6-311+G(d,p) basis set 
and tight convergence criteria. The gas phase Gibbs energies (G0298) were calculated for each 
isolated species using the following equation: 
G
0
298 = E + ZPVE + H0®298 – TS
0
298. 
The gas phase acidities DacidG were determined as the Gibbs energies of deprotonation of 
the substrates R-H (R-H(g) ® R
-
(g) + H
+
(g)) by the following formula: 
DacidG = G
0
298(R
-) + G0298(H
+) - G0298(RH). 
Whereas the solvent influence was treated by using the polarized continuum model (PCM) 
with the default parameters for THF,20 the PCM energies EPCM were calculated at the 
B3LYP/6-311+G(d,p) level using geometries optimized for isolated structures. The Gibbs 
energies in solution Gs were calculated for each species by the equation: 
Gs = G
0
298 + EPCM - E. 
The pKa values were calculated by means of the following homodesmic reaction: 
R-H(s) + Het
-
(s) ® R
-
(s) + Het-H(s), 
where Het-H is an appropriate heterocycle with experimentally known pKa value. In this 
study, 1-propylpyrazole was chosen as reference compound since its pKa value in THF found 
by Fraser et al,17 35.9, was supposed to be close to those for the investigated substrates. 
Within this approach the Gibbs energy of the homodesmic reaction (DrGs) and the pKa 
value are linked together by the following equation: 
r s
a a
1
p (R - H) p (Het - H)
ln10
D
= + ×
G
K K
RT
. 
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It is obvious that the compounds 2b and 8 exist in form of several rotamers due to sterical 
interaction between adjacent hydrogens or/and heteroatom lone pairs. In such cases, the data 
on Scheme 9 (and Supplementary data) refer to the most stable ones. 
There are several potential deprotonation sites in the investigated substrates. When 
comparing the CH acidity in gas-phase (see Supplementary data) and in THF solution 
(Scheme 9), the correlation can be easily seen. Investigation of gas-phase CH acidity (see 
Supplementary data) is of a great importance because these values are free of solvent 
influence and can be used for acidity scale development. The calculated values of gas-phase 
acidity of the investigated compounds lie within the range of 360 to 381 kcal mol-1, which is 
typical for weak CH acids. 
When analyzing the pKa values distribution for the substrates, one can notice that the 5 
position of the triazole ring is clearly the most acidic for 1a, 2a and 2b. According to our 
previous experience, these absolute pKa values below 30 should hint the regioselectivities 
unequivocally. In contrast, for 8, CH acidities of the same magnitude should lead to poor 
selectivity. 
2.3. Discussion 
The calculations of the CH acidities in THF (Scheme 9) allowed us to comment the 
regioselectivities observed in the course of the reactions. 
When treated with the lithium-zinc base, the substrates 1a, 2a and 2b were first attacked at 
the 5 position of the triazole ring. This could be easily rationalized since the 5 position is 
clearly the most acidic of these substrates, with pK
a
 values of 27.7, 28.4 and 27.1, 
respectively. Using the base in excess with the substrate 2b led to the formation of the 
diiodides 7b and 7b’, a result that could be due to rather low pKa values of 32.6 and 30.2, 
respectively at the 3 and 5 position of the 2-thienyl group. 
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To rationalize the formation of a mixture from 8 using the base prepared from 
ZnCl2·TMEDA (0.5 equiv) and LiTMP (1.5 equiv), the pKa values in THF solution of 8 were 
compared with those of 2-phenyl-1,2,3-triazole (4a), which was deprotometalated at its 4 
position under the same reaction conditions (Scheme 10).6h When 4-substituted by a strongly 
electron-withdrawing trifluoromethoxy group, which is known to exhibit a long range effect,21 
the phenyl group becomes more prone to deprotonation and can compete with the triazolyl 
ring. Such an effect could be at the origin of the observed formation of a mixture of iodides 
from 8. 
34.9
40.2
42.2
42.4
N N
N
OCF3
8
N
NN
33.7
35.8
33.3
4a  
Scheme 10. Comparison of pKa(THF) values of 4a vs 8. 
2.4. Biological evaluation 
Due to their structural similarity with the resveratrol skeleton, most of the synthesized 
derivatives were biologically evaluated. As a preliminary screening, ten of these triazoles (the 
compounds 4c-f, 4c’-g’ and 8) were assessed for their antibacterial activities against a 
representative sample of the bacterial species, the most frequently encountered at the Hospital 
and responsible of healthcare-associated infections (HAI): Escherichia coli, Pseudomonas 
aeruginosa, Staphylococcus aureus and Enterococcus faecalis (Table 1). Bacteria were 
treated with different concentrations of compounds (range 1 to 256 μg.mL-1). For all the 
bacteria tested, both Gram-positive and Gram-negative, we were able to determine 
antibacterial activities (i.e. determination of the Minimum Inhibitory Concentration). More 
interesting, even if we observe globally a weak antibacterial activity for these compounds, all 
of them have an antibacterial activity, and to our knowledge, this is the first time that this kind 
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of antibacterial activity is described against these pathogens. On particular interest, the 4,2’-
diaryl derivatives 4e’ and 4f’ as well as the 4-aryl derivatives 4e and 4f showed higher 
antibacterial activities (with MICs = 64 μg.mL-1). Nevertheless, at this stage it is difficult to 
speculate on the possibility to have promising antibacterial candidates. But we believe that 
this triazole derivatives could be of interest, and it is necessary to have more data (for 
example, synthesize other derivatives, or to conduct Structure Activity Relationships studies) 
to be able to obtain or identify potent antibacterial candidates. 
Table 1. Antibacterial activity MICs (μg.mL-1) of the compounds 4c-f, 4c’-g’, 8 and ATB 
(reference antibiotic) obtained by broth microdilution method, according to CLSI guidelines 
(n = 2, see Supplementary data) 
Bacteria 4c 4d 4e 4f 4c’ 4d’ 4e’ 4f’ 4g’ 8 ATB 
Escherichia coli 
ATCC 25922 
128 128 128 128 256 256 128 128 128 256 4a 
Staphylococcus aureus 
ATCC 25923 
256 256 128 256 256 256 128 64 128 256 <1b 
Staphylococcus aureus 
ATCC 29213 
>256 128 64 256 128 256 128 128 256 256 <1b 
Enterococcus faecalis 
ATCC 29212 
128 128 64 128 128 256 128 128 256 128 <1c 
Pseudomonas aeruginosa 
ATCC 27853 
128 128 128 64 128 256 64 128 128 128 8d 
a Amoxicillin. 
b Oxacillin. 
c Vancomycin. 
d Ticarcillin. 
 
Ten of these triazoles were also assessed for their antiproliferative activities against MDA-
MB-231 cell line. Indeed, MDA-MB-231 is an estrogen-receptor negative human breast 
adenocarcinoma cell line currently used as model for antiproliferative assays with resveratrol 
analogues.22 Cells were treated with different concentrations of compounds (ranging from 1 to 
150 µM). The discrimination was done at 100 µM. After 24 h treatment, some compounds 
were found of particular interest (Table 2). The 4,2’-diaryl derivatives 4c’, 4e’, 4f’ and 4g’ 
showed higher antiproliferative activities than the 4-aryl derivatives 4c, 4d, 4e and 4f. The 
methoxy-substituted derivative 4d’ displayed a weaker effect on the viability than the 
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hydroxy analogue 4e’. Moreover, the effect of the trifluoromethyl group of 8, highlighted by 
Pagliai et al,12 seems to be confirmed in this experiment. The antiproliferative evaluation of 
the five molecules 4c’, 4e’-g’ and 8 was pursued by using a 48 h treatment time. Cell survival 
continued to decrease, and less than 5% of the cells treated with 100 µM of 4f’ survived after 
48 h. More interestingly, treatment with 25 µM of 4f’ still led to a strong antiproliferative 
effect with 22.0% ±1.4% after the same duration (data not shown). Half maximal inhibitory 
concentrations (IC50) were measured and proved to be 17.5 ±0.7 µM for 4f’ and 67.0 ±1.4 µM 
for 8 (Table 3). 
Table 2. Antiproliferative activity of the compounds 4c-f, 4c’-g’, 8 and resveratrol (reference 
compound) against MDA-MB-231 cell line (results are expressed as a percentage of survival 
determined by the MTT assay after 24 or 48 h of treatment at a concentration of 100 μM; 
results are mean ± SEM of two independent experiments; nd: not determined). 
Compound 4c 4d 4e 4f 4c’  
After 24 h 85.5 ± 4.9 94.0 ± 0.0 102.0 ± 0.0 66.0 ± 1.4 49.0 ± 0.0  
After 48 h nd nd nd nd 23.0 ± 1.4  
Compound 4d’ 4e’ 4f’ 4g’ 8 resveratrol 
After 24 h 75.0 ± 4.2 54.5 ± 0.7 44.0 ± 4.2 40.5 ± 4.5 58.5 ± 2.5 93.4 ± 2.9 
After 48 h nd 11.0 ± 1.4 2.5 ± 1.5 11.0 ± 4.2 24.0 ± 0.0 60.3 ± 6.4 
Table 3. Half maximal inhibitory concentration (IC50) of MDA-MB-231 cells proliferation 
treated by the compounds 4c’, 4e’-g’, 8 and resveratrol (reference compound) (the cells were 
treated with different concentrations of the compounds during 48 h, and survival was assessed 
by the MTT assay; results are mean ± SEM of two determinations). 
Compound 4c’ 4e’ 4f’ 4g’ 8 resveratrol 
IC50 (μM) 52.0 ± 5.7 40.0 ± 2.8 17.5 ± 0.7 45.5 ± 2.1 67.0 ± 1.4 129.9 ± 3.6 
3. Conclusions 
The different 1-aryl triazoles involved in the deprotometalation-iodolysis sequence were 
functionalized at their most acidic site, which is the 5 position of the aza-ring. By increasing 
the amount of base, it proved possible to also deprotonate the aryl group connected to the 
azole. 
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In the case of 2-phenyl-1,2,3-triazole, the 4-iodo and 4,2’-diiodo derivatives were involved 
in Suzuki coupling to afford 4-aryl and 4,2’-diaryl compounds, which were evaluated for 
biological activities. This synthesis of triazole derivatives is promising for the generation of 
potent antiproliferative compounds. 
4. Experimental 
4.1. General 
Metalation reactions were performed under an argon atmosphere. THF was distilled over 
sodium/benzophenone. Column chromatography separations were achieved on silica gel (40-
63 μm). Melting points were measured on a Kofler apparatus. IR spectra were taken on a 
Perkin-Elmer Spectrum 100 spectrometer. 1H and 13C Nuclear Magnetic Resonance (NMR) 
spectra were recorded on a Bruker Avance III spectrometer at 300 and 75 MHz, respectively. 
1H chemical shifts (δ) are given in ppm relative to the solvent residual peak, 13C chemical 
shifts are relative to the central peak of the solvent signal.23 Mass spectra (HRMS) 
measurements were performed at the CRMPO (Centre Régional de Mesures Physiques de 
l'Ouest) of Rennes using a Waters Q-TOF 2 instrument in positive electrospray CI mode. 
4.1.1. Crystallography 
The samples were studied with graphite monochromatized Mo-Ka radiation (l = 0.71073 
Å). X-ray diffraction data were collected at T = 150(2) K (compounds 4e, 5a, 6a, 7b) or 
294(2) K (compound 4d) using APEXII Bruker-AXS diffractometer. The structure was 
solved by direct methods using the SIR97 program,24 and then refined with full-matrix least-
square methods based on F2 (SHELX-97)25 with the aid of the WINGX program.26 All non-
hydrogen atoms were refined with anisotropic atomic displacement parameters. Except 
oxygen linked hydrogen atom that was introduced in the structural model through Fourier 
difference maps analysis (4e), H atoms were finally included in their calculated positions. 
Molecular diagrams were generated by ORTEP-3 (version 2.02).26 
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4.2. 1-Phenyl-1H-1,2,3-triazole (1a). Compound 1a was prepared by adapting a procedure 
described.8 A mixture of Cu2O (0.12 g, 0.80 mmol), 1,2,3-triazole (0.48 mL, 8.0 mmol), 1,10-
phenanthroline (0.29 g, 1.6 mmol), iodobenzene (1.1 mL, 9.6 mmol) and 
tetramethylammonium fluoride (2.2 g, 24 mmol) was heated under argon at 120 °C for 48 h. 
CH2Cl2 (10 mL) was added to the residue. After filtration over celite, the organic phase was 
washed with brine (2 x 5 mL) and the solvent was evaporated. The crude product was purified 
by chromatography over silica gel (eluent: CH2Cl2/heptane 1:1 to CH2Cl2/AcOEt 1:1) to afford 
the pure compound in 47% yield as an orange powder: mp 58 °C; 1H NMR (CDCl3, 300 
MHz) 7.42-7.49 (m, 1H), 7.51-7.58 (m, 2H), 7.74-7.78 (m, 2H), 7.88 (br s, 1H), 8.03 (d, 1H, J 
= 0.9 Hz). The 1H NMR data are in accordance with those previously described.27 13C NMR 
(CDCl3, 75 MHz) 120.8 (2CH), 121.9 (CH), 129.0 (CH), 129.9 (2CH), 134.6 (CH), 137.2 (C). 
4.3. General procedure 1 for the synthesis of the 1-aryl 1H-1,2,4-triazoles 2a,b.
9 A 
mixture of CuI (0.10 g, 0.50 mmol), the required azole (10 mmol), K3PO4 (4.4 g, 20 mmol), 
the required halide (12 mmol) and N,N’-dimethylethylenediamine (0.11 mL, 1.0 mmol) in 
DMF (5 mL) was degased and heated under argon at 110 °C for 72 h. After filtration over 
celite (washing using AcOEt) and removal of the solvents, the crude product is purified by 
chromatography over silica gel (the eluent is given in the product description). 
4.3.1. 1-Phenyl-1H-1,2,4-triazole (2a). Compound 2a was prepared from 1,2,4-triazole 
(0.69 g) and iodobenzene (1.4 mL) using the general procedure 1, and was isolated (eluent: 
heptane/AcOEt 7:3) in 96% yield as a yellow powder: mp 48 °C (lit.28 46 °C); 1H NMR 
(CDCl3, 300 MHz) 7.42 (m, 1H), 7.53 (m, 2H), 7.71 (m, 2H), 8.15 (s, 1H), 8.74 (s, 1H); 
13C 
NMR (CDCl3, 75 MHz) 120.1 (2CH), 128.3 (CH), 129.9 (2CH), 137.1 (C), 140.9 (CH), 152.7 
(CH). 
4.3.2. 1-(2-Thienyl)-1H-1,2,4-triazole (2b). Compound 2b was prepared from 1,2,4-
triazole (0.69 g) and 2-iodothiophene (1.3 mL) using the general procedure 1, and was 
isolated (eluent: heptane/AcOEt 4:1) in 70% yield as a pale yellow powder: mp 62 °C; IR 
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(ATR): 3440, 3110, 1781, 1556, 1497, 1464, 1403, 1355, 1272, 1221, 1199, 1141, 1028, 
1012, 942, 845, 733, 699, 670 cm-1; 1H NMR (CDCl3, 300 MHz) 7.02 (dd, 1H, J = 5.4 and 3.9 
Hz), 7.19 (dd, 1H, J = 3.6 and 1.2 Hz), 7.21 (dd, 1H, J = 5.4 and 1.5 Hz), 8.07 (s, 1H), 8.45 (s, 
1H); 13C NMR (CDCl3, 75 MHz) 117.8 (CH), 122.8 (CH), 126.4 (CH), 138.8 (C), 142.0 (CH), 
152.6 (CH). HRMS (ASAP): calcd for C6H6N3S [M+H]
+ 152.0282, found 152.0284. 
4.3.3. 2-(4-Trifluoromethoxyphenyl)-2H-1,2,3-triazole (8). Compound 8 was prepared 
by adapting a procedure described.13 A degased solution of Pd2(dba)3 (20 mg, 90 μmol) and 2-
di-tert-butylphosphino-3,4,5,6-tetramethyl-2′ ,4′ ,6′ -triisopropyl-1,1′ -biphenyl (104 mg, 0.22 
mmol) in toluene (6 mL) was heated at 120 °C for 5 min and transferred to a degased mixture 
of K3PO4 (5.1 g, 24 mmol), 1,2,3-triazole (0.83 mL, 14 mmol) and 1-bromo-4-
(trifluoromethoxy)benzene (1.8 mL, 12 mmol) in toluene (6 mL). The resulting mixture was 
heated under argon at 120 °C for 24 h. CH2Cl2 (30 mL) was added, the organic phase was 
washed with NH4Cl-saturated water (10 mL) and brine (10 mL), and the solvent was 
evaporated. The crude product was purified by chromatography over silica gel (eluent: 
heptane/AcOEt 95:5) to afford the pure compound in 96% yield as a beige powder: mp < 50 
°C; IR (ATR): 1606, 1511, 1411, 1386, 1251, 1207, 1193, 1152, 1100, 1084, 1056, 962, 949, 
921, 852, 821, 731, 664 cm-1; 1H NMR (CDCl3, 300 MHz) 7.32-7.36 (m, 2H), 7.82 (s, 2H), 
8.11-8.15 (m, 2H); 13C NMR (CDCl
3
, 75 MHz) 120.4 (2CH), 120.6 (q, C, J = 256 Hz), 122.0 
(2CH), 136.0 (2CH), 138.4 (C), 148.3 (C); 19F NMR (CDCl3, 282 MHz) -58.0. 
4.4. General procedure 2 for the deprotonative metalation followed by iodolysis. To a 
stirred, cooled (0°C) solution of 2,2,6,6-tetramethylpiperidine (0.50 mL, 3.0 mmol) in THF (5 
mL) was added BuLi (about 1.6 M hexanes solution, 3.0 mmol). After 15 min at 0°C, 
ZnCl2·TMEDA (0.25 g, 1.0 mmol) was added, and the mixture was stirred for 15 min at this 
temperature before introduction of the substrate (2.0 mmol). After 2 h at room temperature, a 
solution of I2 (0.74 g, 3.0 mmol) in THF (5 mL) was added. The mixture was stirred overnight 
before addition of an aqueous saturated solution of Na2S2O3 (10 mL) and extraction with 
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CH2Cl2 (3 x 20 mL). The combined organic layers were dried over Na2SO4 and concentrated 
under reduced pressure before purification by flash chromatography on silica gel. 
4.4.1. 5-Iodo-1-phenyl-1H-1,2,4-triazole (6a). Compound 6a was prepared from 1-
phenyl-1H-1,2,4-triazole (2a) using the general procedure 2 and was isolated (eluent: 
heptane/AcOEt 4:1) in 51% yield as a white powder: mp 109 °C; IR (ATR): 3066, 2244, 
1598, 1499, 1475, 1364, 1323, 1273, 1165, 994, 908, 761, 730, 693, 666 cm-1; 1H NMR 
(CDCl3, 300 MHz) 7.54 (br s, 5H), 8.10 (s, 1H); 
13C NMR (CDCl3, 75 MHz) 99.8 (C), 126.1 
(2CH), 129.4 (2CH), 129.8 (CH), 137.5 (C), 155.0 (CH). HRMS (ASAP): calcd for C8H7IN3 
[M+H]+ 271.9685, found 271.9684. Crystal data for 6a (CCDC 1058467). C8H6IN3, M = 
271.06, monoclinic, P 21/c, a = 6.7529(2), b = 7.2343(2), c = 18.0011(6) Å, β = 95.0770(10) °, 
V = 875.95(5) Å3, Z = 4, d = 2.055 g cm-3, μ = 3.600 mm-1. A final refinement on F2 with 2000 
unique intensities and 109 parameters converged at ωR(F2) = 0.0636 (R(F) = 0.0252) for 1886 
observed reflections with I > 2σ(I). 
4.4.2. 5-Iodo-1-(2-thienyl)-1H-1,2,4-triazole (6b). Compound 6b was prepared from 1-
(2-thienyl)-1H-1,2,4-triazole (2b) using the general procedure 2 and was isolated (eluent: 
heptane/AcOEt 4:1) in 95% yield as a yellow powder: mp 66 °C; IR (ATR): 3465, 3101, 
2643, 1549, 1474, 1323, 1267, 1247, 1160, 1031, 945, 847, 699, 676 cm-1; 1H NMR (CDCl3, 
300 MHz) 7.07 (dd, 1H, J = 5.5 and 3.8 Hz), 7.32 (dd, 1H, J = 3.8 and 1.4 Hz), 7.38 (dd, 1H, 
J = 5.5 and 1.4 Hz), 8.06 (s, 1H); 13C NMR (CDCl3, 75 MHz) 102.5 (C), 124.9 (CH), 125.7 
(CH), 125.9 (CH), 137.6 (C), 155.0 (CH). HRMS (ASAP): calcd for C6H5IN3S [M+H]
+ 
277.9249, found 277.9247. 
4.4.3. 2-(2-Iodo-4-trifluoromethoxyphenyl)-2H-1,2,3-triazole (9a). Compound 9a was 
formed (23% estimated yield) from 2-(4-trifluoromethoxyphenyl)-2H-1,2,3-triazole (8) using 
the general procedure 2 and a pure fraction was isolated (eluent: heptane) as a yellow powder: 
mp < 50 °C; IR (ATR): 2930, 1593, 1511, 1495, 1410, 1252, 1217, 1200, 1171, 1065, 1026, 
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962, 952, 884, 823, 736, 671 cm-1; 1H NMR (CDCl3, 300 MHz) 7.35 (ddq, 1H, J = 8.7, 2.7 and 
0.9 Hz), 7.52 (d, 1H, J = 8.7 Hz), 7.85-7.87 (m, 1H), 7.89 (s, 2H); 13C NMR (CDCl3, 75 MHz) 
92.8 (C), 120.4 (q, C, J = 258 Hz), 121.3 (CH), 128.6 (CH), 132.7 (CH), 136.0 (2CH), 141.9 
(C), 149.4 (C); 19F NMR (CDCl3, 282 MHz) -57.9. 
4.4.4. 4-Iodo-2-(2-iodo-4-trifluoromethoxyphenyl)-2H-1,2,3-triazole (10). Compound 
10 was formed (19% estimated yield) from 2-(4-trifluoromethoxyphenyl)-2H-1,2,3-triazole 
(8) using the general procedure 2 and was identified by its 1H NMR spectra: 1H NMR (CDCl3, 
300 MHz) 7.33-7.36 (m, 1H), 7.51 (d, 1H, J = 9.0 Hz), 7.85-7.86 (m, 1H), 7.93 (s, 1H). 
4.4.5. 4-Iodo-2-(4-trifluoromethoxyphenyl)-2H-1,2,3-triazole (9b). Compound 9b was 
formed (6% estimated yield) from 2-(4-trifluoromethoxyphenyl)-2H-1,2,3-triazole (8) using 
the general procedure 2 and was identified by its 1H NMR spectra: 1H NMR (CDCl3, 300 
MHz) 7.33-7.36 (m, 2H), 7.86 (s, 1H), 8.07-8.10 (m, 2H). 
4.5. General procedure 3 for the deprotonative metalation followed by iodolysis. To a 
stirred, cooled (0°C) solution of 2,2,6,6-tetramethylpiperidine (0.50 mL, 3.0 mmol) in THF (5 
mL) was added BuLi (about 1.6 M hexanes solution, 3.0 mmol). After 15 min at 0°C, 
ZnCl2·TMEDA (0.25 g, 1.0 mmol) was added, and the mixture was stirred for 15 min at this 
temperature before introduction of the substrate (1.3 mmol). After 2 h at room temperature, a 
solution of I2 (0.74 g, 3.0 mmol) in THF (5 mL) was added. The mixture was stirred overnight 
before addition of an aqueous saturated solution of Na2S2O3 (10 mL) and extraction with 
CH2Cl2 (3 x 20 mL). The combined organic layers were dried over Na2SO4 and concentrated 
under reduced pressure before purification by flash chromatography on silica gel. 
4.5.1. 5-Iodo-1-phenyl-1H-1,2,3-triazole (5a). Compound 5a was prepared from 1-
phenyl-1H-1,2,3-triazole (1a) using the general procedure 3 and was isolated (eluent: CH2Cl2) 
in 89% yield as a white powder: mp 134 °C; 1H NMR (CDCl
3
, 300 MHz) 7.53-7.59 (m, 5H), 
7.87 (s, 1H); 13C NMR (CDCl3, 75 MHz) 78.7 (C), 125.9 (2CH), 129.3 (2CH), 130.1 (CH), 
  
20 
 
136.5 (C), 141.8 (CH). HRMS (ASAP): calcd for C8H7IN3 [M+H]
+ 271.9685, found 271.9690. 
Crystal data for 5a (CCDC 1058464). C8H6IN3, M = 271.06, monoclinic, P 21/n, a = 
5.11980(10), b = 33.1939(9), c = 5.15960(10) Å, β = 91.3720(10) °, V = 876.60(3) Å3, Z = 4, d 
= 2.054 g cm-3, μ = 3.598 mm-1. A final refinement on F2 with 2015 unique intensities and 145 
parameters converged at ωR(F2) = 0.091 (R(F) = 0.0441) for 1980 observed reflections with I 
> 2σ(I). 
4.5.2. 5-Iodo-1-(2-iodo-5-thienyl)-1H-1,2,4-triazole (7b). Compound 7b was obtained 
from 1-(2-thienyl)-1H-1,2,4-triazole (2b) using the general procedure 3 (eluent: 
heptane/AcOEt 9:1 to 7:3) in 59% estimated yield. The analyses were obtained from a pure 
fraction: beige powder; mp 142 °C; IR (ATR): 3056, 2923, 1552, 1474, 1369, 1331, 1265, 
1160, 953, 795, 734, 703 cm-1; 1H NMR (CDCl3, 300 MHz) 7.01 (d, 1H, J = 4.0 Hz), 7.24 (d, 
1H, J = 4.0 Hz), 8.03 (s, 1H); 13C NMR (CDCl3, 75 MHz) 74.4 (C), 101.8 (C), 126.1 (CH), 
135.7 (CH), 142.0 (C), 155.3 (CH). Crystal data for 7b (CCDC 1058468). C6H3I2N3S, M = 
402.97, orthorhombic, P c a b, a = 7.5513(4), b = 11.9393(5), c = 21.3208(9) Å, V = 
1922.22(15) Å3, Z = 8, d = 2.785 g cm-3, μ = 6.710 mm-1. A final refinement on F2 with 2201 
unique intensities and 109 parameters converged at ωR(F2) = 0.0709 (R(F) = 0.0289) for 1955 
observed reflections with I > 2σ(I). 
4.5.3. 5-Iodo-1-(3-iodo-2-thienyl)-1H-1,2,4-triazole (7b'). Compound 7b’ was obtained 
from 1-(2-thienyl)-1H-1,2,4-triazole (2b) using the general procedure 3 (eluent: 
heptane/AcOEt 9:1 to 7:3) in 28% estimated yield: 1H NMR (CDCl3, 300 MHz) 7.14 (d, 1H, J 
= 5.7 Hz), 7.47 (d, 1H, J = 5.7 Hz), 8.10 (s, 1H); 13C NMR (CDCl3, 75 MHz) 84.8 (C), 105.1 
(C), 129.0 (CH), 134.0 (CH), 155.8 (CH), 1C not seen. 
4.6. General procedure 4 for the Suzuki-type mono-coupling.
14 A degassed solution of 
4-iodo-2-phenyl-2H-1,2,3-triazole (4b, 0.14 g, 0.5 mmol) and the required boronic acid (0.5 
mmol), CsF (0.15 g, 1.0 mmol), Pd(dba)2 (13 mg, 25 μmol, 5 mol.%) and PPh3 (13 mg, 50 
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μmol, 10 mol.%) in dioxane (10 mL) was heated at 105 °C for 18 h. The reaction mixture was 
then diluted with Et2O (50 mL) and washed with H2O (2 x 10 mL). The combined organic 
layers were dried over Na2SO4 and concentrated under reduced pressure before purification by 
flash chromatography on silica gel. 
4.6.1. 2,4-Diphenyl-2H-1,2,3-triazole (4c). Compound 4c was prepared from 
phenylboronic acid (61 mg) using the general procedure 4 and was isolated (eluent: 
heptane/AcOEt 9.5:0.5) in 70% yield as a yellow powder: mp < 50 °C; IR (ATR): 3040, 
2925, 1598, 1498, 1480, 1460, 1395, 1343, 978, 964, 845, 766, 753, 710, 687, 660 cm-1; 1H 
NMR (CDCl3, 300 MHz) 7.33-7.54 (m, 6H), 7.89-7.93 (m, 2H), 8.06 (s, 1H), 8.13-8.17 (m, 
2H); 13C NMR (CDCl3, 75 MHz) 118.9 (2CH), 126.3 (2CH), 127.5 (CH), 128.9 (CH), 129.1 
(2CH), 129.4 (2CH), 130.2 (C), 132.7 (CH), 140.0 (C), 149.0 (C). 
4.6.2. 4-(2,5-Dimethoxyphenyl)-2-phenyl-2H-1,2,3-triazole (4d). Compound 4d was 
prepared from 2,5-dimethoxyphenylboronic acid (182 mg) using the general procedure 4, but 
using 2 equiv of boronic acid, and was isolated (eluent: heptane/AcOEt/Et2O 98:1:1) in 54% 
yield as a yellow powder: mp 68-70 °C; IR (ATR): 2940, 2835, 1724, 1598, 1526, 1489, 
1465, 1436, 1382, 1335, 1313, 1270, 1222, 1172, 1074, 1044, 1023, 992, 965, 859, 801, 754, 
734, 704, 689, 661 cm-1; 1H NMR (CDCl3, 300 MHz) 3.87 (s, 3H), 3.92 (s, 3H), 6.89-6.97 (m, 
2H), 7.35 (tt, 1H, J = 7.3 and 1.2 Hz), 7.47-7.53 (m, 2H), 7.74 (dd, 1H, J = 2.7 and 0.6 Hz), 
8.15-8.19 (m, 2H), 8.32 (s, 1H); 13C NMR (CDCl3, 75 MHz) 56.0 (CH3), 56.2 (CH3), 112.8 
(CH), 113.4 (CH), 115.5 (CH), 118.9 (2CH), 119.7 (C), 127.4 (CH), 129.4 (2CH), 136.2 
(CH), 140.0 (C), 145.6 (C), 151.5 (C), 154.0 (C). Crystal data for 4d (CCDC 1058466). 
C16H15N3O2, M = 281.31, monoclinic, P 21/n, a = 15.2065(19), b = 4.8810(6), c = 19.365(2) Å, 
β = 104.952(5) °, V = 1388.7(3) Å3, Z = 4, d = 1.346 g cm-3, μ = 0.091 mm-1. A final 
refinement on F2 with 3180 unique intensities and 192 parameters converged at ωR(F2) = 
0.1327 (R(F) = 0.0459) for 2105 observed reflections with I > 2σ(I). 
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4.7. General procedure 5 for the Suzuki-type mono-coupling. A degassed solution of 4-
iodo-2-phenyl-2H-1,2,3-triazole (4b, 0.14 g, 0.5 mmol) and the required boronic acid (0.5 
mmol), Na2CO3 (0.12 g, 1.1 mmol), PdCl2 (2 mg, 10 μmol, 2 mol.%) and PPh3 (8 mg, 30 
μmol, 6 mol.%), in H2O (6 mL), EtOH (5 mL) and 1,2-dimethoxyethane (8 mL), was heated 
at 90 °C for 24 h. The reaction mixture was then diluted with H2O (10 mL) and extracted with 
CH2Cl2 (3 x 10 mL). The combined organic layers were dried over Na2SO4 and concentrated 
under reduced pressure before purification by flash chromatography on silica gel. 
4.7.1. 4-(4-Hydroxyphenyl)-2-phenyl-2H-1,2,3-triazole (4e). Compound 4e was 
prepared from 4-hydroxyphenylboronic acid (69 mg) using the general procedure 5 and was 
isolated (eluent: heptane/AcOEt 4:1) in 98% yield as a beige powder: mp 178-179 °C (lit.29 
177-179 °C); IR (ATR): 3306, 3044, 2926, 2853, 1713, 1615, 1595, 1497, 1461, 1390, 1265, 
1224, 1200, 1174, 979, 966, 835, 752, 736, 705, 661 cm-1; 1H NMR (CDCl3, 300 MHz) 6.91-
6.95 (m, 2H), 7.32-7.38 (m, 1H), 7.47-7.53 (m, 2H), 7.78-7.81 (m, 2H), 7.98 (s, 1H), 8.10-
8.14 (m, 2H), OH not seen; 13C NMR (CDCl3, 75 MHz) 116.0 (2CH), 118.9 (2CH), 123.0 (C), 
127.4 (CH), 127.9 (2CH), 129.4 (2CH), 132.2 (CH), 140.1 (C), 148.8 (C), 156.4 (C). Crystal 
data for 4e (CCDC 1058465). C14H11N3O, M = 237.26, orthorhombic, P c a n, a = 7.5313(3), 
b = 17.1106(9), c = 17.6845(10) Å, V = 2278.9(2) Å3, Z = 8, d = 1.383 g cm-3, μ = 0.091 mm-1. 
A final refinement on F2 with 2591 unique intensities and 166 parameters converged at ωR(F2) 
= 0.0954 (R(F) = 0.0394) for 2092 observed reflections with I > 2σ(I). 
4.7.2. 4-(4-Aminophenyl)-2-phenyl-2H-1,2,3-triazole (4f). Compound 4f was prepared 
from 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.11 g) using the general 
procedure 5 and was isolated (eluent: CH2Cl2/heptane 8:2) in 87% yield as a white powder: 
mp 134-136 °C; IR (ATR): 3438, 3420, 3355, 2925, 2855, 1730, 1622, 1609, 1596, 1497, 
1488, 1459, 1392, 1342, 1285, 1183, 1073, 977, 967, 832, 753, 692, 657 cm-1; 1H NMR 
(CDCl3, 300 MHz) 3.8 (br s, 2H), 6.75-6.79 (m, 2H), 7.33 (tt, 1H, J = 7.5 and 1.2 Hz), 7.45-
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7.52 (m, 2H), 7.69-7.72 (m, 2H), 7.95 (s, 1H), 8.09-8.13 (m, 2H); 13C NMR (CDCl3, 75 MHz) 
115.4 (2CH), 118.8 (2CH), 120.5 (C), 127.2 (CH), 127.5 (2CH), 129.3 (2CH), 132.0 (CH), 
140.1 (C), 147.3 (C), 149.3 (C). HRMS (ESI): calcd for C14H13N4 [M+H]
+ 237.1140, found 
237.1137. 
4.8. General procedure 6 for the Suzuki-type bis-coupling. A degassed solution of 4-
iodo-2-(2-iodophenyl)-2H-1,2,3-triazole (4b’, 0.20 g, 0.5 mmol) and the required boronic acid 
(2.0 mmol), Na2CO3 (0.12 g, 1.1 mmol), PdCl2 (2 mg, 10 μmol, 2 mol.%) and PPh3 (8 mg, 30 
μmol, 6 mol.%), in H2O (6 mL), EtOH (5 mL) and 1,2-dimethoxyethane (8 mL), was heated 
at 90 °C for 24 h. The reaction mixture was then diluted with H2O (10 mL) and extracted with 
CH2Cl2 (3 x 10 mL). The combined organic layers were dried over Na2SO4 and concentrated 
under reduced pressure before purification by flash chromatography on silica gel. 
4.8.1. 2-(1,1'-(2-Biphenyl))-4-phenyl-2H-1,2,3-triazole (4c’). Compound 4c’ was 
prepared from phenylboronic acid (0.24 g) using the general procedure 6 and was isolated 
(eluent: heptane/AcOEt 100:0 to 95:5) in 90% yield as a yellow oil: IR (ATR): 3053, 1599, 
1506, 1485, 1458, 1440, 1392, 1265, 1092, 1074, 978, 969, 847, 766, 757, 732, 694 cm-1; 1H 
NMR (CDCl3, 300 MHz) 7.13-7.16 (m, 2H), 7.26-7.29 (m, 3H), 7.35-7.43 (m, 3H), 7.49-7.56 
(m, 3H), 7.69-7.74 (m, 3H), 7.90 (s, 1H); 13C NMR (CDCl3, 75 MHz) 126.3 (2CH), 126.5 
(CH), 127.5 (CH), 128.4 (CH), 128.4 (2CH), 128.6 (2CH), 128.8 (CH), 129.1 (2CH), 129.6 
(CH), 130.3 (C), 131.5 (CH), 132.3 (CH), 137.9 (C), 138.7 (C), 138.9 (C), 148.6 (C). HRMS 
(ASAP): calcd for C20H16N3 [M+H]
+ 298.1344, found 298.1340. 
4.8.2. 2-(4’-Methoxy-1,1'-(2-biphenyl))-4-(4-methoxyphenyl)-2H-1,2,3-triazole (4d’). 
Compound 4d’ was prepared from 4-methoxyphenylboronic acid (0.30 g) using the general 
procedure 6 and was isolated (eluent: heptane/AcOEt 100:0 to 7:3) in 75% yield as a yellow 
oil: IR (ATR): 2940, 2938, 1613, 1519, 1488, 1456, 1290, 1246, 1177, 1033, 979, 969, 832, 
765, 732, 703, 665 cm-1; 1H NMR (CDCl3, 300 MHz) 3.77 (s, 3H), 3.84 (s, 3H), 6.79-6.83 (m, 
2H), 6.93-6.97 (m, 2H), 7.04-7.08 (m, 2H), 7.43-7.53 (m, 3H), 7.66-7.70 (m, 3H), 7.84 (s, 
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1H); 13C NMR (CDCl3, 75 MHz) 55.3 (CH3), 55.4 (CH3), 113.8 (2CH), 114.4 (2CH), 122.9 
(C), 126.6 (CH), 127.5 (2CH), 127.8 (CH), 129.4 (CH), 129.6 (2CH), 131.1 (C), 131.3 (CH), 
131.7 (CH), 137.5 (C), 138.6 (C), 148.3 (C), 159.0 (C), 160.1 (C). HRMS (ESI): calcd for 
C22H19N3NaO2 [M+Na]
+ 380.1375, found 380.1378. 
4.8.3. 2-(4’-Hydroxy-1,1'-(2-biphenyl))-4-(4-hydroxyphenyl)-2H-1,2,3-triazole (4e’). 
Compound 4e’ was prepared from 4-hydroxyphenylboronic acid (0.28 g) using the general 
procedure 6 and was isolated (eluent: heptane/AcOEt 100:0 to 0:1) in 92% yield as a yellow 
oil: IR (ATR): 3054, 1707, 1615, 1594, 1516, 1489, 1456, 1367, 1265, 1223, 1173, 1105, 
971, 836, 732, 703 cm-1; 1H NMR (CDCl3, 300 MHz) 6.62-6.66 (m, 2H), 6.79-6.82 (m, 2H), 
6.90-6.93 (m, 2H), 7.39-7.48 (m, 3H), 7.52-7.56 (m, 2H), 7.62 (d, 1H, J = 7.2 Hz), 7.81 (s, 
1H), 2 OH not seen; 13C NMR (CDCl3, 75 MHz) 115.4 (2CH), 116.0 (2CH), 122.3 (C), 126.7 
(CH), 127.7 (2CH), 127.8 (CH), 129.6 (CH), 129.7 (2CH), 130.6 (C), 131.3 (CH), 131.6 
(CH), 137.7 (C), 138.3 (C), 148.6 (C), 155.6 (C), 156.8 (C). HRMS (ESI): calcd for 
C20H15N3NaO2 [M+Na]
+ 352.1062, found 352.1064. 
4.8.4. 2-(4’-Amino-1,1'-(2-biphenyl))-4-(4-aminophenyl)-2H-1,2,3-triazole (4f’). 
Compound 4f’ was prepared from 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 
(0.44 g) using the general procedure 6 and was isolated (eluent: heptane/MeOH 100:0 to 0:1) 
in 73% yield as a pink oil: IR (ATR): 3360, 1622, 1515, 1488, 1454, 1388, 1287, 1181, 971, 
830, 766, 736 cm-1; 1H NMR (CDCl3, 300 MHz) 3.7 (br s, 4H), 6.54-6.58 (m, 2H), 6.70-6.74 
(m, 2H), 6.89-6.92 (m, 2H), 7.41 (ddd, 1H, J = 7.5, 5.7 and 3.3 Hz), 7.47-7.51 (m, 2H), 7.55-
7.58 (m, 2H), 7.59-7.64 (m, 1H), 7.79 (s, 1H); 13C NMR (CDCl
3
, 75 MHz) 114.9 (2CH), 115.2 
(2CH), 120.6 (C), 126.6 (CH), 127.3 (CH), 127.3 (2CH), 128.8 (C), 129.2 (CH), 129.3 (2CH), 
131.0 (CH), 131.2 (CH), 137.9 (C), 138.4 (C), 145.6 (C), 146.9 (C), 148.6 (C). HRMS (ESI): 
calcd for C20H18N5 [M+H]
+ 328.1562, found 328.1561. 
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4.8.5. 2-(3’-Chloro-1,1'-(2-biphenyl))-4-(3-chlorophenyl)-2H-1,2,3-triazole (4g’). 
Compound 4g’ was prepared from 3-chlorophenylboronic acid (0.31 g) using the general 
procedure 6 and was isolated (eluent: heptane/AcOEt 100:0 to 4:1) in 83% yield as a yellow 
oil: IR (ATR): 3061, 1564, 1500, 1470, 1453, 1411, 1264, 1099, 1081, 994, 968, 887, 847, 
804, 787, 763, 735, 703, 695, 683 cm-1; 1H NMR (CDCl3, 300 MHz) 6.94 (dt, 1H, J = 7.5 and 
1.5 Hz), 7.17 (d, 1H, J = 7.8 Hz), 7.19-7.25 (m, 2H), 7.32-7.35 (m, 2H), 7.49-7.59 (m, 4H), 
7.68-7.76 (m, 2H), 7.83 (s, 1H); 13C NMR (CDCl3, 75 MHz) 124.3 (CH), 126.3 (CH), 126.3 
(CH), 126.7 (CH), 127.6 (CH), 128.8 (CH), 128.9 (CH), 128.9 (CH), 129.5 (CH), 129.7 (CH), 
130.3 (CH), 131.4 (CH), 131.8 (C), 132.5 (CH), 134.2 (C), 135.0 (C), 136.3 (C), 138.4 (C), 
140.6 (C), 147.5 (C). HRMS (ASAP): calcd for C20H14
35Cl2N3 [M+H]
+ 366.0565, found 
366.0561. 
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